handling of urate is realized by a network of uptake and efflux transporters, including members of drug transporter families such as solute carrier proteins and ATP-binding cassette transporters. Solute carrier family 2, member 9 (SLC2A9), is one key factor of this so called "urate transportosome." The aim of the present study was to understand the transcriptional regulation of SLC2A9 and to test whether identified factors might contribute to a coordinated transcriptional regulation of the transporters involved in urate handling. In silico analysis and cell-based reporter gene assays identified a hepatocyte nuclear factor (HNF)4␣-binding site in the promoter of SLC2A9 isoform 1, whose activity was enhanced by transient HNF4␣ overexpression, whereas mutation of the binding site diminished activation. HNF4␣ overexpression induced endogenous SLC2A9 expression in vitro. The in vivo role of HNF4␣ in the modulation of renal SLC2A9 gene expression was supported by findings of quantitative real-time RT-PCR analyses and chromatin immunoprecipitation assays. Indeed, mRNA expression of SLC2A9 and HNF4␣ in human kidney samples was significantly correlated. We also showed that in renal clear cell carcinoma, downregulation of HNF4␣ mRNA and protein expression was associated with a significant decline in expression of the transporter. Taken together, our data suggest that nuclear receptor family member HNF4␣ contributes to the transcriptional regulation of SLC2A9 isoform 1. Since HNF4␣ has previously been assumed to be a modulator of several urate transporters, our findings support the notion that there could be a transcriptional network providing synchronized regulation of the functional network of the urate transportosome.
Members of the solute carrier group of membrane transport proteins, such as SLC22, SLC17, and SLC2, as well as members of the ATP-binding cassette (ABC) transporter family are part of this network of urate transporters (as recently summarized in Ref. 52 ).
In the urate transportosome, urate transporter 1 (URAT1; SLC22A12), organic anion transporter (OAT)4 (SLC22A11), and OAT10 (SLC22A13) are assumed to govern urate reabsorption at the apical membrane (3, 8, 11) . OAT1 (SLC22A6) and OAT3 (SLC22A8) are expressed at the basolateral membrane and facilitate urate uptake from the circulation into tubular cells (17, 31, 38) . Cellular elimination of urate at the apical membrane is mediated by voltage-driven Na ϩ -P i cotransporter (NPT)1 (SLC17A1) and NPT4 (SLC17A3), and the ATP-dependent transporter ABCG2 and ABCC4 (18, 19, 46, 51) .
In accordance with the assumed pivotal role of transporters in urate handling, several single-nucleotide polymorphisms (SNPs) located in transporter genes, including ABCG2, SLC17A1, SLC17A3, SLC22A11, and SLC2A12, have been identified in genome-wide association studies as predictive for serum urate levels (35) . In addition, SNPs in the PDZ domain containingprotein 1 (PDZK1) gene have been reported to be associated with urate homeostasis. This membrane-associated scaffold protein contains several PDZ domains, which interact with specific C-terminal PDZ-binding motifs of other proteins, thereby coordinating membrane localization, signal transduction, and posttranslational modifications of its targets (21) . Functional interaction of PDZK1 has been shown for uptake transporters URAT1 and OAT4 as well as for efflux transporters NPT1 and ABCG2, thereby suggesting that PDZK1 stabilizes the apical urate transporter network (1, 10, 27, 40) .
However, the aforementioned genome-wide association studies have shown that genetic variants of solute carrier family 2, member 9 (SLC2A9), are of major relevance for human urate homeostasis, whereby the minor alleles of the identified SNPs were associated with lower serum urate levels, indicating that SLC2A9 is a key factor of the urate transportosome (23, 47) .
SLC2A9 belongs to the facilitated glucose transporter protein family class II. In contrast to other members of this transporter superfamily, SLC2A9 not only transports hexoses but also mediates an electrogenic uniport of urate (4, 33, 47, 50) . Expression of SLC2A9 has been observed in various embryonic and adult tissues, including the kidney, liver, placenta, and pancreas (33) . Importantly, the SLC2A9 gene is a template for several mRNA transcripts coding for at least two different isoforms with different N-terminal (2) . Notably, those transcripts exhibit different cellular localization. Indeed, whereas SLC2A9 isoform 1 is expressed at the basolateral membrane of polarized cells, SLC2A9 isoform 2 has been reported to sort to the apical site (2) .
However, even if SLC2A9 is assumed to be a major factor in urate homeostasis and although numerous studies of the past 10 yr have focused on the other functional components of the urate transportosome, little is known about the coordination of the transcellular transport of urate as realized in tubular cells.
Therefore, we hypothesized that there should be a mechanism providing synchronized transcriptional regulation of the transporters involved in the network. The aim of the present study was to understand the transcriptional regulation of SLC2A9 and to test whether identified factors might contribute to the coordination of expression and therefore the activity of the urate transportosome.
MATERIALS AND METHODS
Tissue samples. Human kidney tissue samples were obtained from patients undergoing nephrectomy after diagnosis of renal carcinoma. Tissue samples were collected after written informed consent from the patients. This study was approved by the local ethics committee of the Medical Faculty of the University of Greifswald (III UV 12/03). Preparation of nonmalignant transformed and neoplastic samples was followed by snap freezing in liquid nitrogen and storage at Ϫ80°C until further use. The snap-frozen samples were pulverized in a mixer mill.
Cell culture. HeLa cells (CCL-2, American Type Culture Collection) were maintained in DMEM with GlutaMAX-I and 1 mM sodium pyruvate (Invitrogen, Darmstadt, Germany), and HepG2 cells were cultured in RPMI 1640 with GlutaMAX-I (Invitrogen), each supplemented with 10% FBS (Invitrogen). Cell culture was performed at 37°C with 5% CO 2 in a humidified atmosphere.
RNA extraction and quantitative real-time RT-PCR. Total mRNA from different human tissues was commercially obtained from BioCat (Heidelberg, Germany) and used for the quantification of tissuespecific gene expression. Total mRNA from human surgical renal tissue and cell lines was isolated using NucleoSpin silica-membrane technology provided by Macherey-Nagel (Dueren, Germany) according to the manufacturer's instructions. DNase-treated total mRNA (2 g) was primed with random hexamers and reverse transcribed using the RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany). Quantitative real-time PCR was performed using predeveloped 6-carboxyfluorescein (FAM)-labeled TaqMan probes, as shown in Table 1 (Life Technologies, Darmstadt, Germany), an equivalent of 20 ng cDNA, TaqMan Gene Expression Master Mix (Life Technologies), and the 7900 HT Fast Real-Time PCR System (Life Technologies). Expression was normalized to that of polymerase (RNA) II (DNA directed) polypeptide A using the ⌬C t method (where C t is threshold cycle).
For correlation analysis of SLC2A9, the number of transcripts was determined using reference samples each containing defined amounts of plasmid DNA harboring the cDNA sequence of the respective target gene. The copy number of transcripts per microliter of reference sample was determined by calculating the molecular weight of the corresponding reference plasmids using an internet-based program (http://www.bioinformatics.org/sms2/reference.html) after spectrophotometric quantification of plasmid DNA content using BioPhotometer plus and Cuvette G1.0 (Vaudaux-Eppendorf, Schönenbuch, Switzerland).
Western blot analysis. For protein isolation, pulverized tissue samples were homogenized and solubilized by 15 min of incubation with ice-cold RIPA buffer (25 mM Tris·HCl, 150 mM NaCl, 1% Triton X-100, 0.01% sodium deoxycholate, and 0.1% SDS) containing 1:100 protease inhibitor cocktail (Sigma-Aldrich, Taufkirchen, Germany) and by syringing with a 20-gauge needle. Cell debris was removed by 15-min centrifugation at 13,000 g. Protein lysates were stored at Ϫ80°C. Protein content was quantified using the Pierce BCA Protein Assay Kit (ThermoScientific, Bonn, Germany) and an Infinite M200 microplate reader (Tecan, Crailsheim, Germany). For Western blot analysis, protein samples were separated by SDS-PAGE and electrotransferred to nitrocellulose membranes using a Mini-PROTEAN electrophoresis and tank blotting system (Bio-Rad, Munich, Germany). Subsequently, membranes were blocked with 5% BSA in 1ϫ Tris-buffered saline-Tween 20 at room temperature for 1 h followed by an overnight incubation with the respective primary antibody at 4°C. I-19 goat polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was used for the detection of ␤-actin, sc21631 goat polyclonal antibody (Santa Cruz Biotechnology) was used for the detection of SLC2A9, and ab41898 mouse monoclonal antibody (K9218, Abcam, Cambridge, UK) was used for the detection of HNF4␣ (each diluted 1:1,000). Binding of the specific antibody was visualized using horseradish peroxidase-labeled secondary antibodies (each diluted 1:2,000), Pierce ECL Plus Western Blotting Substrate (ThermoScientific), and the ChemiDoc XRS imaging system (BioRad).
Cloning of wild-type and mutated promoter fragments. The promoter of SLC2A9 was subcloned into pGL3-basic (Promega, Mannheim, Germany) using the primers shown in Table 2 . After amplification from human genomic DNA, the PCR fragments were purified and restricted using the indicated enzymes (Table 2) . After ligation and amplification in Escherichia coli DH5␣, the cloned sequence was controlled by Sanger sequencing (MWG Eurofins, Ebersberg, Germany). To introduce sequence variations, the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA) was used following the manufacturer's instructions.
Reporter gene assays. For reporter gene assays, cells were seeded at a density of 1 ϫ 10 5 in serum-free media in 24-wells 24 h before transfection. Cells were transfected with 975 ng of the indicated variants of reporter gene vector pGL3-basic, 25 ng of pRL-TK (Promega) for normalization of transfection efficiency, and the indicated amounts of the eukaryotic expression vector pEF6/V5- His containing the coding region of HNF4␣ and retinoid X receptor (RXR)␣ using Nanofectin (PAA, Pasching, Germany) after supplementation of media with 10% FBS. Eukaryotic expression vectors were kindly provided by Rommel Tirona (University of Western Ontario, London, ON, Canada). After 48 h, luciferase activities were determined using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luminescence was quantified using a microplate reader (Tecan Infinite M200) and the instrument's software, iControl (Tecan). 
Chromatin innmunoprecipitation assay. For chromatin immunoprecipitation (ChIP), 300 mg snap-frozen, pulverized tissue or 2 ϫ 10 6 cells and the EZ-ChIP Kit were used (Merck, Zug, Switzerland). In detail, chromatin was fixed with 1% formaldehyde for 15 min before the in vivo cross-linking was quenched with glycin. Cells were washed with PBS twice and lysed with 1.6 ml SDS lysis buffer. Lysates were sheared on ice with 35 repeats of 30-s pulses set to 0.9 and 90% amplitude followed by 45-s rests using the ultrasonic processor (UP200S) and a 1-mm tip (Hielscher, Teltow, Germany). Cross-linked protein/DNA complexes were immunoprecipitated using anti-RNA polymerase II antibody (no. 05-623B, Merck) as a positive control, anti-HNF4␣ antibody (K9218, Abcam), and ChIP-blocked protein G-conjugated agarose beads. Treatment with mouse IgG (no. 12-371B, Merck) served as a negative control. Protein-DNA crosslinking was reversed, and DNA was purified using silica membrane spin columns. Purified DNA (0.5 l) was applied by PCR using 0.1 l Platinum Taq DNA polymerase, 1ϫ PCR buffer, 1.5 mM MgCl 2, 400 M dNTP mix, 0.3 M sense primer (5=-CATGATCAAATTGCCA-CACTTC-3=), and 0.3 M antisense primer (5=-GACCCCA-GACTCTGCCAAG-3=) in a total reaction volume of 25 l. The temperature profile of the ChIP-PCR was as follows: preincubation at 95°C (2 min) followed by 40 cycles of 95°C (30 s), 60°C (30 s), and 72°C (30 s), and final extension at 72°C (2 min). The resultant PCR products were separated by 2.5% agarose electrophoresis.
RESULTS
Profiling of the urate transportosome in human kidney samples. Expression of the genes assumed to be part of the urate transportosome, namely,
(breast cancer resistance protein), and ABCC4 (multidrug resistance protein 4) were assessed in 29 human kidney samples using quantitative real-time RT-PCR. Reference samples each containing a defined amount of plasmid DNA harboring the cDNA sequence of the respective transporter were used to define the copy number of the corresponding transcripts. All transporters were detected in the tested tissue samples, including SLC2A9 isoforms 1 and 2.
However, in the following reported experiments, we focused on the analysis of SLC2A9 isoform 1. Importantly, as shown in Fig. 1 , A-C, Spearman regression analysis revealed a statistically significant positive correlation of SLC2A9 isoform 1 mRNA expression with apical urate uptake transpor- Positive correlation of mRNA levels of SLC2A9 isoform 1 and HNF4␣ in the human kidney. Based on the observed correlation of SLC2A9 isoform 1 expression with other members of the urate transportosome, we hypothesized that there should be a factor coordinately regulating a gene network summarizing the urate transportosome. It seems noteworthy that the nuclear receptor HNF4␣ has been previously reported to be involved in the modulation of expression of some of the above-mentioned urate transporters, namely, SLC17A1 (NPT1), SLC17A3 (NPT4), SLC22A6 (OAT1), and SLC22A8 (OAT3) (9, 30, 31, 48) . To provide evidence that this nuclear receptor could play a role in the regulation of the renal urate transporter gene network, expression of HNF4␣ was tested in human kidney samples, revealing expression levels similar to hepatic tissue (data not shown).
In addition, Spearman regression analysis showed a statistically significant positive correlation of SLC2A9 isoform 1 and HNF4␣ mRNA expression [R ϭ 0.6103 (CI: 0.0337-0.8024), P ϭ 0.0004] in kidney tissue samples, suggesting that there might be an involvement of HNF4␣ in the modulation of SLC2A9 expression (Fig. 1D) .
Transfection with the HNF4␣ expression vector induces endogenous SLC2A9 isoform 1 mRNA expression levels in HeLa cells. Transactivation experiments were conducted to test whether HNF4␣ modulates SLC2A9 expression in a cellular system. In detail, 48 h after transfection of HeLa cells with a eukaryotic expression vector encoding for the nuclear receptor HNF4␣, detection of endogenous SLC2A9 isoform 1 mRNA expression revealed enhanced endogenous expression of this transporter (mean mRNA expression relative to pEF6/V5-His control Ϯ SD: 67.5 Ϯ 4.5; Fig. 2 ). However, SLC2A9 isoform Fold change in expression relative to transfection with pEF6/V5-His-empty HNF4α 1.0 ± 0.6 0.9 ± 0.8 507.8 ± 0.6** 746.6 ± 0.6** SLC2A9 isoform 1 1.0 ± 1.7 0.5 ± 2.1 67.5 ± 4.5* 164.9 ± 9.9* NR0B2 (SHP1) 1.0 ± 0.6 0.9 ± 0.6 24.0 ± 0.7** 40 .0 ± 0.6** Fig. 2 . In transactivation experiments, HeLa cells were transfected with the indicated amounts of eukaryotic expression vectors pEF6/V5-His-HNF4␣ and pEF6/ V5-His-RXR␣ (where RXR is the retinoid X receptor). After 48 h, endogenous SLC2A9 mRNA expression levels were assessed using real-time quantitative RT-PCR according to the 2 Ϫ⌬⌬Ct method (where Ct is threshold cycle, with method referring to the expression of cells transfected with pEF6/V5-His control). The resultant PCR products were separated by 3% agarose gel electrophoresis. NR0B2, nuclear receptor subfamily 0, group B, member 2; SHP1, small heterodimer partner 1. Data are means Ϯ SD from three independent experiments performed as triplicates. *P Ͻ 0.05 and **P Ͻ 0.005 by paired t-test (two-tailed).
1 expression was further enhanced by cotransfection of RXR␣ (mean mRNA expression relative to pEF6/V5-His control Ϯ SD: 164.9 Ϯ 9.9). Enhanced expression in the presence of HNF4␣, which was further increased in the presence of RXR␣, was also observed for the well-known HNF4␣ target gene nuclear receptor subfamily 0, group B, member 2 (NR0B2), which is also called small heterodimer partner 1 (mean mRNA expression relative to pEF6/V5-His control Ϯ SD: 24.0 Ϯ 0.7 for HNF4␣ and 40.0 Ϯ 0.6 for HNF4␣ ϩ RXR␣; Fig. 2) .
Identification of two putative gene-regulating modules of SLC2A9. Initially, to identify regulative promoters of SLC2A9 isoforms 1 and 2, respectively, fragments of the intronic regions upstream of exons 0a, 1a, 2a, and 1b were subcloned into pGL3-basic (Fig. 3A) . The subcloned SLC2A9 promoter fragments were used in cell-based dual luciferase reporter gene assays and showed no transcriptional activity upstream of the first transcribed exons (0a and 1a) of isoform 2 (Fig. 3B) . However, there was an increased basal activity of the reporter gene in HeLa cells transfected with SLC2A9 promoter fragments Ϫ740 to ϩ161 bp, representing a fragment 5=-upstream of exon 2a (isoform 2), and Ϫ976 to Ϫ55 bp, representing a fragment 5=-upstream of exon 1b (isoform 1). Basal transcriptional promoter activity of SLC2A9 isoform 1 was further restricted to a fragment encompassing Ϫ231 to Ϫ55 bp using 5=-deletion constructs of the identified promoter fragment in cell-based luciferase assays (Fig. 3C) .
In silico analysis of the core promoter of SLC2A9 isoform 1 and in vitro mutation of putative transcription factor-binding sites. As shown in Fig. 4A , several potential transcription factor-binding motifs in the SLC2A9 isoform 1 promoter fragment (Ϫ231 to Ϫ55 bp) were identified by in silico analysis using internet-based programs such as TFSEARCH and NUBISCAN (14, 34) . In addition to CCAAT/enhancer binding protein (C/EBP), octamer transcription factor 1 (Oct1), c-Myb, E26 transformation specific (Ets), PU.1, and NF-B binding motifs, an inverted/a direct repeat of one hexanucleotide (IR1, DR0), a putative HNF4␣ response element, was identified in position Ϫ84 to Ϫ73 bp of the promoter fragment. Sequence alignment showed high similarity of this motif with HNF4␣ cis elements in the promoters of known target genes of this nuclear receptor, such as human ␣ 1 -antitrypsin or coagulation factor X (Fig. 4B) (12, 16) .
Notably, after mutation of this particular binding site, an intense loss of basal luciferase activity of promoter fragments Ϫ231 to Ϫ55 bp as well as Ϫ976 to Ϫ55 bp was observed in HepG2 cells containing high endogenous mRNA expression of HNF4␣ (Fig. 5A ). However, no such effect was observed when we tested the impact of the mutated HNF4␣-binding site on the , and alternative exons specific for isoform 1 (exon 1b) and isoform 2 (exons 0, 1a, and 2a). Fragments of the intronic regions 5=-upstream of exons 0, 1a, 2a, and 1b were subcloned into luciferase vector pGL3-basic. B: subsequent dual luciferase reporter gene assays with these promoter fragments in HeLa cells revealed two gene-regulating modules in the SLC2A9 gene, with one being 5=-upstream of the first exon (exon 1b) of SLC2A9 isoform 1. *P Ͻ 0.05 by paired t-test (two-tailed). C: using deletion constructs, basal activity of the module of isoform 1 was restricted to a region from Ϫ231 to Ϫ55 bp relative to the translational start site of isoform 1. Data in B and C are means Ϯ SD from three independent experiments performed as triplicates. ***P Ͻ 0.0005 by ANOVA with Dunnett's multiple-comparison test.
basal promoter activity in HeLa cells harboring low endogenous HNF4␣ (Fig. 5B) .
Furthermore, the binding sites of C/EBP, Oct1, c-Myb, NF-B, and Ets were mutated to determine their involvement in basal promoter activity. Mutation of C/EBP, Oct1, and c-Myb motifs did not alter luciferase activity of both promoter fragments in HeLa cells (data not shown). However, there was a loss of promoter activity of both fragments by 64 Ϯ 8% and 58 Ϯ 9% when the NF-B motif in position Ϫ107 to 96 bp was mutated and subsequently used in a dual reporter gene assay.
Importantly, mutation of the Ets-binding motif in position Ϫ119 to Ϫ114 bp resulted in a significant decrease of reporter gene activity of promoter fragments Ϫ976 to Ϫ55 bp and Ϫ231 to Ϫ55 bp by 94 Ϯ 2% and 91 Ϯ 1%, respectively (data not shown).
Transfection eukaryotic HNF4␣ expression vector showed significantly higher luciferase activity than promoter fragments cotransfected with pEF6/V5-His control vector (mean luciferase activity relative to pEF6/V5-His control Ϯ SD: 8.2 Ϯ 1.8; Fig.  6A ). Similar results were obtained using eukaryotic RXR␣ expression vector, which had increased activity relative to pEF6/V5-His control (3.4 Ϯ 1.2). Simultaneous cotransfection with both HNF4␣ and RXR␣ resulted in an even higher enhancement of promoter activity (mean luciferase activity relative to pEF6/V5-His control Ϯ SD: 607.0 Ϯ 162.4). Importantly, reduced transactivation by HNF4␣ was observed when we performed mutational analysis of the putative HNF4␣-binding site in the core promoter of SLC2A9 isoform 1 (Fig. 6B) . In detail, dual luciferase reporter gene assays of subcloned SLC2A9 isoform 1 promoter fragments Ϫ231 to Ϫ55 bp and Ϫ976 to Ϫ55 bp with the mutated sequence of the HNF4a-binding site showed significant differences in the induction of luciferase activity by 50% compared with the wild type when cotransfected with the eukaryotic HNF4␣ expression vector.
In vivo binding of HNF4␣ to the SLC2A9 isoform 1 promoter region (Ϫ231 to Ϫ55 bp). To test whether HNF4␣ binds to the SLC2A9 isoform 1 promoter, a ChIP assay was performed using DNA isolated from human kidney samples, which revealed an in vivo interaction of this nuclear receptor with the herein identified promoter region of SLC2A9 isoform 1, as shown in Fig. 7D .
Dedifferentiation of the urate transportosome in human renal cell carcinoma. Since we were able to show that HNF4␣ is a transcriptional modulator of SLC2A9 isoform 1 expression and since HNF4␣ expression has been previously described as being deregulated in renal cell carcinoma, we asked whether human renal cell carcinogenesis is also associated with altered expression of the herein reported target gene SLC2A9 and other components of the urate transportosome.
Real-time quantitative RT-PCR and Western blot analysis comparing paired nontransformed and malignant transformed renal tissue samples showed lower expression of both SLC2A9 isoform 1 and HNF4␣ in the carcinoma samples (Fig. 8 ). Those differences in mRNA expression were also observed for PDZK1 and apical and basolateral urate uptake transporters OAT1 (SLC22A6), OAT3 (SLC22A8), OAT4 (SLC22A11), OAT10 (SLC22A13), and URAT1 (SLC22A12) as well as apical efflux transporter NPT1 (SLC17A1), with lower mRNA levels in renal tumor samples (Fig. 8, A-G) . There was no significant difference in expression in tumor samples and paired controls for NPT4 (SLC17A3; Fig. 8H ). In contrast, ABCG2 expression showed slightly lower expression in nonmalignant transformed tissue than in tumor samples (Fig. 8I) .
DISCUSSION
Taken together, we studied the transcriptional regulation of SLC2A9 isoform 1, which is part of the urate transportosome characterized by a functional network of urate uptake and efflux transporters (8). Our investigations not only support the notion that the transcriptional activity of SLC2A9 is regulated by two promoters but also show that the nuclear receptor HNF4␣ is one of the factors transcriptionally modulating the expression of isoform 1 of this urate transporter.
The assumption of a HNF4␣-dependent regulation of SLC2A9 was initially supported by expression studies revealing a positive correlation of SLC2A9 isoform 1 and HNF4␣ mRNA levels in the human kidney. Further evidence was provided by the observations that transient HNF4␣ overexpression induced endogenous SLC2A9 isoform 1 mRNA levels in cells and enhanced reporter gene activity of vector constructs harboring the promoter region of SLC2A9 isoform 1. The involvement of HNF4␣ in the regulation of SLC2A9 isoform 1 was further supported by the in silico identification of a potential HNF4␣-binding motif in the core promoter of the transporter gene. Importantly, site-directed mutagenesis of this binding motif reduced HNF4␣-dependent transactivation of the promoter. The high similarity of the herein studied HNF4␣ response element with sequences previously identified in the 5=-untranslated region of known HNF4␣ target genes, such as ␣-antitrypsin, or coagulation factor X indicates that the identified element is a representative HNF4␣-binding motif (6, 12, 16, 25, 43) . HNF4␣ has not only been shown to be expressed in the human kidney but also has been reported to be significantly downregulated in human kidney tumors, thereby playing a role in carcinogenesis and tumor progression (26, 39, 41) . Similar results have been observed in hepatocellular carcinoma (24).
The herein reported findings of an in vivo binding of HNF4␣ to the SLC2A9 isoform 1 promoter region together with the findings on the downregulation of SLC2A9 and HNF4␣ in human renal cell carcinoma samples correlate well with the function of HNF4␣ as a modulator of SLC2A9 expression in vivo.
Notably, several components of the urate transportosome, including NPT1 (SLC17A1), NPT4 (SLC17A3), OAT1 (SLC22A6), and OAT3 (SLC22A8), have been previously reported to be target genes of the nuclear receptor HNF4␣, thereby providing the basis for the hypothesis that HNF4␣ is one major determinant of the urate transportosome gene network (9, 30, 31, 48) .
In accordance are the findings of our expression experiments that showed a positive correlation of SLC2A9 isoform 1 expression with those of other members of the urate transportosome in human nonmalignant transformed kidney samples, indicating that members of a physiological network might also be trancriptionally connected. The findings that HNF4␣ expression was significantly reduced in renal cell carcinoma and that mRNA expression of SLC2A9 and expression of other urate transporters followed the same trend support the notion that correlated targets might be regulated in the same way following the same trend of regulation, although a low level of HNF4␣ expression might not be the only reason of downregulation of urate transporters.
However, it seems noteworthy that the role of HNF4␣ is not limited to the regulation of urate transporter expression, as it has been shown to be a regulator of other proximal tubule functions and, importantly, embryonic tubule maturation in general (9) .
Taken together, our findings support the idea that nuclear receptor family member HNF4␣ is not only a modulator of SLC2A9 isoform 1 expression in the kidney but might also be a central regulator of the gene network summarizing the urate transportosome, thereby supporting the above-mentioned hypothesis that expression and activity of genes involved in renal urate handling could be coordinated by a shared regulator or regulatory pathway.
Interestingly, nuclear receptors as transcriptional regulators of gene networks have been widely studied. For example, nuclear receptor family members farnesoid X receptor (NR1H4) and peroxisome proliferator-activated receptor-␣ (NR1C1) are modulators of physiological processes such as bile acid synthesis or lipid homeostasis, respectively (7). Moreover, in the context of Relative expression levels calculated according to the 2 Ϫ⌬⌬Ct method refer to mean expression values of all analyzed nonmalignant transformed kidney samples (n ϭ 27). ***P Ͻ 0.0005 by paired t-test (two-tailed). C: Western blot analysis of HNF4␣ and SLC2A9 of paired samples of malignant and nonmalignant transformed renal tissue. D: PCR products (2.5% agarose) of a chromatin immunoprecipitation assay using a 300-mg human kidney sample fixed with formaldehyde and sheared by sonication. PCR using primers specific for 177-bp region of the SLC2A9 promoter was performed after immunoprecipitation with 1 g mouse anti-HNF4 antibody. As an input control, 1% sonicated cell lysate was used. Immunoprecipitation with anti-RNA polymerase II antibody served as a positive control, and incubation with mouse IgG served as a negative control. drug/toxin elimination, the ligand-activated xenosensor pregnane X receptor (PXR; NR1I2) has been a major focus. In general, after binding of activating ligands, which include a variety of drugs in clinical use, PXR translocates into the nucleus, where it enhances expression and therefore activity of a target gene network. This network summarizes uptake transporters, metabolizing enzymes, and efflux transporters (44) . It is therefore assumed that PXR is a key factor adjusting hepatic metabolic activity to drug exposure, thus being a driving force of drug-drug interactions. One example of clinical relevance is the observed loss of therapeutic efficacy of the immunodepressant cyclosporine A in the presence of the antidepressant St.
John's wort, resulting in graft rejection of transplanted patients (36) . Indeed, PXR activation by hyperforin, a constituent of St. John's wort, induces cytochrome P-450 (CYP)3A4 and P-glycoprotein (ABCB1) expression, thereby increasing hepatic metabolism and elimination of their substrate cyclosporine A (29, 32) .
Similar to PXR, the nuclear receptor family member HNF4␣ dimerizes and binds to specific response elements in the 5=-untranslated region of target genes, as reported by Sladek and colleagues (41) . Interestingly, it has been previously reported that HNF4␣ is important for the above-mentioned PXR-mediated transactivation of CYP3A4 (45) . In addition, HNF4␣ has been shown to be a major modulator of hepatic gene expression and to directly regulate several drug transporters and metabolizing enzymes, indicating its regulatory role in drug disposition gene expression (20) .
Taken together, the nuclear receptor HNF4␣ may not only coordinate homeostasis of the physiological substrate urate but also the renal clearance of pharmacological compounds and therefore pharmacokinetics by modulating expression of membrane proteins involved in physiological and pharmacological transport. However, it is still unclear whether activity of HNF4␣ is modulated by ligand-mediated activation or by transcriptional induction. On the one hand, there is evidence that fatty acyl-CoA thioesters and linoleic acid act as potent activators of HNF4␣ (5, 15, 49) . On the other hand, it is known that HNF4␣ itself is a target of the homeobox transcription factor HNF1␣ (13) . Since HNF1␣ itself is a target of HNF4␣ and has been previously reported to modulate the transcription of several components of the urate transportosome, it seems beyond the scope of this report to decide on the role of HNF1␣ in this regulatory pathway (22, 37, 39, 42, 48) .
In conclusion, we demonstrate that the nuclear receptor HNF4␣ is one of the factors transcriptionally modulating SLC2A9, thereby providing further evidence that this transporter is part of the urate transportosome. Additionally, we show that the urate transporter network is disturbed in human renal cell carcinoma.
